Total Payments
$2,881
2021 Payments
$210.66
Companies
27
Transactions
208
Medicare Patients
2,652
Medicare Billing
$267,163
Payment Breakdown by Category
Food & Beverage$2,657 (92.2%)
Education$223.36 (7.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,657 | 199 | 92.2% |
| Education | $223.36 | 9 | 7.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $512.37 | 33 | $0 (2021) |
| Allergan, Inc. | $491.46 | 30 | $0 (2020) |
| GlaxoSmithKline, LLC. | $394.02 | 39 | $0 (2020) |
| PFIZER INC. | $186.29 | 17 | $0 (2020) |
| AbbVie Inc. | $174.24 | 8 | $0 (2021) |
| Astellas Pharma US Inc | $170.44 | 9 | $0 (2019) |
| Orexigen Therapeutics, Inc. | $146.31 | 6 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $131.82 | 12 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $82.51 | 7 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $70.07 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $210.66 | 7 | Novo Nordisk Inc ($142.36) |
| 2020 | $384.11 | 28 | Novo Nordisk Inc ($260.60) |
| 2019 | $899.79 | 65 | Allergan Inc. ($347.04) |
| 2018 | $692.89 | 59 | GlaxoSmithKline, LLC. ($124.75) |
| 2017 | $693.12 | 49 | Orexigen Therapeutics, Inc. ($146.31) |
All Payment Transactions
208 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2021 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: Obesity | ||||||
| 12/17/2021 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $5.17 | General |
| Category: Obesity | ||||||
| 12/02/2021 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $6.23 | General |
| Category: Obesity | ||||||
| 11/16/2021 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $92.19 | General |
| Category: Obesity | ||||||
| 11/16/2021 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $4.41 | General |
| Category: Obesity | ||||||
| 05/07/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $68.30 | General |
| Category: NEUROSCIENCE | ||||||
| 01/12/2021 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: Obesity | ||||||
| 11/20/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $9.96 | General |
| Category: Obesity | ||||||
| 10/08/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $6.90 | General |
| Category: Obesity | ||||||
| 10/01/2020 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $11.47 | General |
| 10/01/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $5.75 | General |
| Category: Obesity | ||||||
| 10/01/2020 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $1.94 | General |
| 07/24/2020 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 07/24/2020 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 07/24/2020 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 07/06/2020 | Novo Nordisk Inc | Saxenda (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Obesity | ||||||
| 03/10/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.85 | General |
| Category: RESPIRATORY | ||||||
| 03/10/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $5.82 | General |
| Category: Obesity | ||||||
| 03/02/2020 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $15.67 | General |
| 03/02/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $6.51 | General |
| Category: Obesity | ||||||
| 02/27/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.80 | General |
| Category: RESPIRATORY | ||||||
| 02/20/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $11.61 | General |
| Category: Obesity | ||||||
| 02/14/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $4.00 | General |
| Category: Obesity | ||||||
| 02/14/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $2.67 | General |
| Category: Obesity | ||||||
| 02/14/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $2.30 | General |
| Category: Obesity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 659 | 1,014 | $191,731 | $73,824 |
| 2022 | 10 | 666 | 1,031 | $181,300 | $66,378 |
| 2021 | 14 | 701 | 1,050 | $157,960 | $75,463 |
| 2020 | 11 | 626 | 912 | $121,665 | $51,497 |
Total Patients
2,652
Total Services
4,007
Medicare Billing
$267,163
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 154 | 328 | $82,000 | $26,082 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 168 | 310 | $55,800 | $18,163 | 32.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 104 | 104 | $23,568 | $12,784 | 54.2% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 20 | 20 | $9,940 | $5,648 | 56.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 51 | 51 | $6,273 | $3,668 | 58.5% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 35 | 42 | $3,640 | $2,112 | 58.0% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 13 | 13 | $4,290 | $2,044 | 47.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 55 | 55 | $3,190 | $1,575 | 49.4% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 25 | 56 | $1,504 | $908.32 | 60.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 22 | 22 | $1,161 | $629.86 | 54.3% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 12 | 13 | $365.00 | $210.60 | 57.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 174 | 361 | $90,250 | $27,796 | 30.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 165 | 342 | $61,560 | $19,709 | 32.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 78 | 78 | $15,756 | $9,722 | 61.7% |
| 90682 | Influenza vaccine, quadrivalent derived from recombinant dna | Office | 2022 | 58 | 58 | $3,364 | $3,300 | 98.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 76 | 76 | $3,116 | $2,074 | 66.6% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 41 | 41 | $3,034 | $1,483 | 48.9% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 21 | 21 | $1,680 | $1,064 | 63.3% |
| 0054A | Adm sarscv2 30mcg trs-sucr b | Office | 2022 | 22 | 22 | $1,628 | $801.07 | 49.2% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 19 | 19 | $665.00 | $400.71 | 60.3% |
| 81003 | Automated urinalysis test | Office | 2022 | 12 | 13 | $247.00 | $28.92 | 11.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 136 | 278 | $56,690 | $23,103 | 40.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 169 | 370 | $49,752 | $21,040 | 42.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 97 | 97 | $19,594 | $12,144 | 62.0% |
| 90670 | Pneumococcal vaccine for injection into muscle | Office | 2021 | 17 | 17 | $6,630 | $4,092 | 61.7% |
About Dr. Jeffrey Peterson, MD
Dr. Jeffrey Peterson, MD is a Sports Medicine healthcare provider based in Greenwood, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1740262716.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Peterson, MD has received a total of $2,881 in payments from pharmaceutical and medical device companies, with $210.66 received in 2021. These payments were reported across 208 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($2,657).
As a Medicare-enrolled provider, Peterson has provided services to 2,652 Medicare beneficiaries, totaling 4,007 services with total Medicare billing of $267,163. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Sports Medicine
- Other Specialties Family Medicine
- Location Greenwood, IN
- Active Since 11/16/2005
- Last Updated 09/13/2023
- Taxonomy Code 207QS0010X
- Entity Type Individual
- NPI Number 1740262716
Products in Payments
- XEN (Device) $252.52
- Saxenda (Drug) $252.26
- TRELEGY ELLIPTA (Drug) $239.92
- CONTRAVE (Drug) $146.31
- VRAYLAR (Drug) $141.01
- ANORO (Drug) $128.56
- CHANTIX (Drug) $122.00
- MYRBETRIQ (Drug) $92.40
- Myrbetriq (Drug) $78.04
- Dexilant (Drug) $68.93
- Trintellix (Drug) $62.56
- Vascepa (Drug) $61.29
- VIBERZI (Drug) $57.44
- NUEDEXTA (Drug) $52.06
- JANUVIA (Drug) $48.16
- Prolia (Biological) $47.21
- LINZESS (Drug) $43.53
- Victoza (Drug) $41.44
- Livalo (Drug) $37.62
- FARXIGA (Drug) $37.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Sports Medicine Doctors in Greenwood
Dr. Sean Calloway, M.d, M.D
Sports Medicine — Payments: $129,917
Sports Medicine $129,917
Mark Dilella, Do, DO
Sports Medicine — Payments: $3,945
Sports Medicine $3,945
Dr. Scott Gudeman, Md, MD
Sports Medicine — Payments: $3,281
Sports Medicine $3,281
Thurman Alvey, D.o, D.O
Sports Medicine — Payments: $1,010
Sports Medicine $1,010
Philip Blaney, M.d, M.D
Sports Medicine — Payments: $474.71
Sports Medicine $474.71
Blake Averill, Md, MD
Sports Medicine — Payments: $389.46
Sports Medicine $389.46